| Literature DB >> 29177196 |
Deirdre A Shires1, Ashley Schnaar1, Maureen D Connolly2, Daphna Stroumsa3.
Abstract
Little is known about general pediatricians' experience and knowledge regarding the care of transgender youth. We surveyed N=50 general pediatricians practicing in an integrated Midwest health system. Few respondents had participated in medical management care for transgender patients, but one-third were willing to do so if training opportunities were made available. Notably, <60% of respondents were comfortable providing routine care for transgender youth. At a minimum, pediatricians need the training to feel capable of providing routine care for transgender pediatric patients. In addition, opportunities for training should be offered to those who are willing to learn about medical management of transgender youth.Entities:
Keywords: GnRH analogues; hormone therapy; pediatrics; transgender youth
Year: 2017 PMID: 29177196 PMCID: PMC5689121 DOI: 10.1089/trgh.2017.0019
Source DB: PubMed Journal: Transgend Health ISSN: 2380-193X
General Pediatricians' Experiences and Willingness to Provide Endocrine Management to Transgender Youth (
| Variable | % |
|---|---|
| Ever cared for transgender pediatric patient | 52.4 |
| Ever counseled a patient/family about gender identity issues | 72.7 |
| GnRH analogues for transgender youth | |
| Ever initiated | 0.0 |
| Ever continued/refilled | 4.8 |
| Willing to initiate | 0.0 |
| Willing to continue/refill | 15.0 |
| Willing to learn how to provide if given opportunity | 30.0 |
| HT for transgender youth | |
| Ever initiated | 0.0 |
| Ever continued/refilled | 4.8 |
| Willing to initiate | 4.8 |
| Willing to continue/refill | 19.0 |
| Willing to learn how to provide if given opportunity | 30.0 |
| Referrals | |
| Ever referred to mental health provider for gender dysphoria diagnosis letter | 45.5 |
| Ever referred to another provider for GnRH analogue or HT | 36.4 |
| Would always refer for GnRH analogue | 55.0 |
| Would always refer for HT | 52.4 |
GnRH, gonadotropin-releasing hormone; HT, hormone therapy.
General Pediatricians' Facilitators and Barriers Related to Caring for Transgender Youth (
| Variable | % |
|---|---|
| Facilitators | |
| Feels capable of providing routine medical care to pediatric transgender patients. | 57.1 |
| Familiar with Lupron/GnRH analogue regimens | 33.3 |
| Familiar with gender-affirming HT regimen | 23.8 |
| Confident in knowledge of the health risks/benefits of GnRH and gender-affirming HT | 14.3 |
| Barriers to caring for transgender youth | |
| Not enough time during office visits to provide gender transition care | 61.9 |
| Not familiar with transition care guidelines | 57.1 |
| Lack of training in transgender-specific pediatric care | 61.9 |
| Do not know mental health providers who will assess/confirm gender dysphoria | 35.0 |
| Lack of exposure to pediatric transgender patients | 23.8 |
| Lack of knowledge about transgender patients among office staff, medical assistants, and/or nursing staff | 23.8 |
| Fear of being sued after irreversible treatments | 4.8 |
General Pediatricians' Knowledge About Caring for Transgender Youth (
| Question | % |
|---|---|
| 1. At what stage should the use of puberty blockers (GnRH) begin in a pediatric patient with persistent gender dysphoria? (check all that apply) | |
| When the patient, parent, and clinician agree | 19.0 |
| Tanner stage 1 | 4.8 |
| Tanner stage 2 | 9.5 |
| Tanner stage 3+ | 4.8 |
| Puberty blockers should never be prescribed to pediatric transgender patients | 4.8 |
| I do not know | 76.2 |
| 2. At what point can the use of cross-sex HT generally begin for a pediatric patient with persistent gender dysphoria? (check all that apply) | |
| When the patient, parent, and clinician agree | 10.0 |
| When the patient has used puberty blockers for at least 2 years | 5.0 |
| Age 16 if the patient has used puberty blockers for at least 2 years | 10.0 |
| Cross-sex HT should never be prescribed to transgender youth | 5.0 |
| I do not know | 80.0 |
| 3. Lupron/GnRH analogue and cross-sex HT can be prescribed to pediatric transgender patients by (check all that apply) | |
| Primary care providers (pediatricians, IM, FM) | 25.0 |
| Psychiatrists | 15.0 |
| Endocrinologists | 40.0 |
| Adolescent medicine providers | 30.0 |
| I do not know | 60.0 |
| 4. Most children whose gender-variant identity persists into adolescence develop an adult transgender identity | |
| True | 40.0 |
| False | 10.0 |
| I do not know | 50.0 |
| 5. Puberty is often a source of significant distress for transgender youth | |
| True | 95.2 |
| False | 0.0 |
| I do not know | 4.8 |
| 6. Gender dysphoria in youth is classified as a mental disorder | |
| True | 4.8 |
| False | 23.8 |
| I do not know | 71.4 |
| 7. Initiating social and medical gender transition for pediatric transgender patients has no impact on their risk of depression | |
| True | 9.5 |
| False | 85.7 |
| I do not know | 4.8 |
| 8. It is the clinician's obligation to disclose a pediatric patient's gender identity to the patient's parent/guardian even if the child does not wish for the parents to know | |
| True | 14.3 |
| False | 61.9 |
| I do not know | 23.8 |
FM, family medicine; IM, internal medicine.